Introduction
Since protein binding may be enhanced by renal failure, it could be argued that the elevated serum leptin The obesity (ob) gene protein, known as leptin (from demonstrated in the present study are due to an excess Greek leptos 'thin'), was cloned in 1994 by Friedman of bound forms of leptin rather than free bioactive et al. [1] and regulates food intake and energy expenditforms. However, a recent study has shown that elevated ure in animal models. Leptin which is exclusively leptin in patients with CRF are due to an increase in produced in the adipocytes, circulates in the blood the free bioactive form of leptin rather than in bound with~50% in free form and the remainder attached forms [4] . to binding proteins. Leptin reaches the brain by a saturable transport mechanism via the blood-brain barrier and, via direct effects on the hypothalamus,
Causes of hyperleptinaemia in chronic renal failure
decreases appetite and increases metabolism. Markedly elevated leptin levels have been reported in patients
As the kidneys are important in clearing several other with obesity, who seem to be insensitive to the endogenpolypeptide hormones such as insulin, parathyroid ous leptin production. It has been proposed that in hormone, and glucagon, it seems reasonable to surmise obese patients there is a defective transport of leptin that leptin also accumulates in the case of renal failure across the blood-brain barrier indicating a resistance due to reduced renal clearance. However, elevated to the central actions of leptin. Treatment with recomserum leptin are not a universal finding in advanced binant leptin induces dramatic 40% weight reduction CRF [8] , and the exact cause of elevated serum leptin in mice [2] , but no results are as yet available regarding in uraemia is not well understood, although there are the weight-reducing effect of recombinant leptin treatdata suggesting that a decrease in glomerular filtration ment on obese humans.
rate [4, 6, 9 , P. Stenvinkel, unpublished data], inflammation [3] and hyperinsulinaemia [8, 10] may affect serum leptin levels in CRF. Leptin, insulin concentrations, and body weight, are interrelated and there is a
Leptin in chronic renal failure
direct correlation between insulin and leptin concentrations in non-uraemic [11] as well as uraemic patients Protein-calorie malnutrition is a common problem in [8, 10] . It has been shown that long-term (72 h) insulin patients with advanced chronic renal failure (CRF ) infusion stimulates leptin secretion in humans [12] . and is associated with increased morbidity and mortalAnother possible reason for elevated leptin levels in ity. Numerous factors contribute to malnutrition, but renal failure is chronic inflammation [3] . It has been reduced food intake due to anorexia is probably the demonstrated that cytokines, such as TNFa and IL-1, most important. The mechanism(s) causing decreased induce both an increase in leptin mRNA concentraappetite in uraemia are not obvious. However, in 1997 tions and anorexia in animals [13] , and this suggests a number of studies demonstrated that CRF patients that elevated leptin concentrations may be one of the with [3] [4] [5] [6] and without [3, 6, 7] ongoing dialysis treatmechanisms by which anorexia is induced during ment have markedly elevated serum leptin without an inflammatory conditions. increase in body fat mass. Since leptin is thought to be an inhibitor of appetite, by restraining the synthesis and release of neuropeptide Y, it has been speculated clinical importance if hyperleptinaemia could be circulating serum leptin is markedly elevated in relation to the per cent fat plasma insulin does not continue to proved to contribute to uraemic anorexia. However, for leptin to suppress appetite in CRF patients we increase [8] . This may imply that markedly elevated serum leptin impair the pancreatic insulin secretion have to assume that leptin is present mostly in its unbound bioactive form and that there is a normal and that hyperleptinaemia could be a factor contributing to impaired glucose tolerance in uraemia. As transport of leptin across the uraemic blood-brain barrier. Young et al. [7] have demonstrated a signific-suggested by Haynes et al. [15] , some of the peripheral actions of leptin may act as a signalling mechanism to ant negative relation between the plasma leptin/body fat ratio and the dietary protein intake in dialysis activate compensatory mechanisms for the potentially deleterious effects of an increased body fat mass. patients, and this is consistent with the concept that leptin contributes to malnutrition. Moreover, data Interestingly, Shek et al. [18] recently demonstrated that chronic increases in CNS leptin concentrations in presented by Heimbü rger et al. [3] suggest that elevated serum leptin may induce anorexia in uraemic patients rats increase heart rate and blood pressure, suggesting a possible role of leptin in obesity hypertension. One with an ongoing inflammatory process. Accordingly, at present there is some evidence indicating that elev-might therefore speculate that if obese and uraemic patients with hyperleptinaemia are resistant to the ated leptin concentrations may mediate anorexia in CRF, but it is obvious that further studies are necessary facilitative effects of leptin on insulin sensitivity and sodium excretion but not resistant to the stimulatory to substantiate this suggestion.
Anorexia, one of the major symptoms of uraemia, effects of leptin on the sympathetic activity, then this explains why sodium sensitive hypertension and insulin is only partly corrected by dialysis. Even if the majority of leptin circulates in the unbound form, the size of resistance are such frequent accompaniments of both obesity and uraemia. Thus, leptin has multiple actions leptin (16 kDa) suggests that leptin will not be cleared by ordinary synthetic dialysis membranes, and accord-that are potentially relevant not only to the control of eating behaviour but also to cardiovascular regulation. ingly several studies have demonstrated that leptin concentrations are not reduced by haemodialysis [4] [5] [6] .
A new and fascinating aspect of the putative peripheral actions of leptin are the recently described However, it remains to be tested whether or not highflux synthetic membranes with greater clearance of proliferative effects of leptin on haematopoietic stem cells suggesting a role for leptin in erythropoiesis. large molecules will decrease serum leptin and improve appetite. In contrast to the unchanged serum leptin Actually, there might be a synergy between leptin and erythropoietin, as discussed by Bennet et al. [19] . The concentrations observed after the initiation of haemodialysis, leptin concentrations increase markedly in bone marrow contains adipocytes in which the ob gene is expressed. It has been speculated that the fat cell patients treated by CAPD [3] . Recently, Heimbü rger et al. [3] demonstrated that 12 months of CAPD content of human bone marrow reflects the requirement for leptin in active haematopoiesis [19] . This treatment was associated with a marked increase in the body fat content. It has been suggested that the may mean that in clinical states with anaemia and insufficient production of erythropoietin, such as CRF, continuous carbohydrate load in CAPD increases body fat mass and consequently serum leptin [3] . However, other haematopoietic factors, such as leptin, will be increasingly important in stimulating erythropoiesis it remains to be proved whether or not elevated leptin concentrations contribute to the low eating drive in [20] . CAPD patients despite their great need for protein and calories [14] .
In addition to its effects on appetite, leptin also
Summary and perspectives
increases energy expenditure by a stimulatory effect on the sympathetic nervous system [for a review see 15].
Ikizler et al. [16 ] have demonstrated that haemodialysis The recent discovery of the ob gene product leptin has markedly increased our understanding of the complex patients have an elevated energy expenditure, and it could be speculated that elevated leptin levels will be physiological system that regulates satiety and eating behaviours. Moreover, as leptin receptor isoforms have one factor contributing to a negative energy balance in uraemia. The kidney has been shown to express now been reported in several peripheral organs, it may be conjectured that leptin, besides having central leptin receptors, and it has been demonstrated that leptin in high doses increases diuresis and natriuresis effects, also has pleiotropic action in the peripheral organs. This suggests that the functional role of leptin in rats without significant effects on renal blood flow and glomerular filtration rate, suggesting a direct tubu-appears to extend beyond the regulation of feeding and metabolism to include other organs and some lar effect [15] . The effects of leptin on insulin metabolism are complex. Whereas it has been demonstrated biological functions of definite interest for the nephrologist. Indeed, recent findings indicate that besides that leptin acutely increases insulin sensitivity in rats [15] , Emilsson et al. [17] reported that leptin receptors regulating appetite leptin may play a role in sympathico-activation, insulin secretion and sensitivity, renal are present in the pancreas and that leptin, in a dosedependent manner, inhibits pancreatic insulin secretion sodium handling and haematopoiesis. Probably other actions of leptin will also soon be discovered. It is in mice. In accordance with this finding, results in predialysis patients indicate that when the level of possible that leptin-receptor antagonists will be avail-9. Cumin F, Baum HP, Levens N. Leptin is cleared from the able for clinical use in the future. It is therefore circulation primarily by the kidney. Int J Obesity 1996; 20: important to determine whether or not hyperleptina- [1120] [1121] [1122] [1123] [1124] [1125] [1126] emic uraemic patients are resistant to the central and 10 The pathogenesis of glomerulonephritis can be conceptu-genic antigens and modulate the inflammatory events which ensue ( Figure 1 ). The discovery of T helper ally divided into immunologic and inflammatory phases ( Figure 1 ). Immune responses to foreign or self antigens lymphocyte subsets (Th1 and Th2) that differ in their cytokine secretion patterns and effector functions has result in formation of nephritogenic lymphocytes, antigen-antibody complexes, and autoantibodies which provided a model for understanding how cytokines regulate pathologic immune and inflammatory responses [2] . initiate an inflammatory cascade in the kidney [1] . The consequence of these immunologic and inflammatory We will briefly summarize the Th1/Th2 hypothesis, how it relates to experimental glomerulonephritis and highprocesses is glomerular and interstitial fibrosis.
T lymphocyte-derived cytokines regulate the cellular light recent studies which question this hypothesis. and humoral arms of the immune response to nephrito- two subpopulations based on their pattern of cyto-tion by Th1 lymphocytes. Th1-and Th2-type cytokines are expressed in rat and mouse kidneys during the kine production [2, 3] . Th1 lymphocytes secrete interleukin-2 ( IL-2), interferon-c (IFNc) and tumour course of glomerulonephritis [4, 5] . It is therefore suggested that a balance between Th1 and Th2 lymphonecrosis factor-b ( TNFb or lymphotoxin). Th2 cells, on the other hand, secrete IL-4, IL-5, IL-6, IL-9, IL-10, cytes determines the outcome of immune-mediated glomerulonephritis [6 ] . and IL-13 ( Figure 2 ). Both cell types originate from the same precursor lymphocyte ( Th0) and their differentiation is determined by cytokines present at time of antigen recognition. The presence of IL-12 and IFNc favor the Th1 phenotype while IL-4 promotes genera-The Th1/Th2 hypothesis and experimental tion of Th2 lymphocytes.
The Th1/Th2 hypothesis

glomerulonephritis
Th1-derived cytokines are considered to promote tissue injury by mediating delayed-type hypersensitivity Several studies have provided evidence that IL-4 pro-(DTH ) reactions, cytotoxic T lymphocyte generation, tects against antibody-mediated glomerulonephritis. By macrophage activation and production of complement comparing the intensity of nephritis between IL-4 genefixing antibodies [2, 3] . In contrast, Th2-derived knockout and wild-type mice, IL-4 was found to be cytokines appear to protect against tissue injury by an endogenous inhibitor of neutrophil influx and subdeviating antibody production towards IgE and non-sequent glomerular inflammation in the heterologous complement fixing subclasses of IgG [2, 3] . They also phase of passive murine anti-glomerular basement suppress DTH reactions and counteract IFNc's actions membrane (anti-GBM ) nephritis [5] . It was also on macrophages.
observed that Brown Norway rats, which exhibit Th1 and Th2 subsets are reciprocally regulated [2, 3] . increased IL-4 production and decreased DTH IFNc inhibits the differentiation and proliferation of responses, are resistant to glomerular injury associated Th2 cells resulting in a dominant Th1 response. On with the autologous phase of accelerated rat anti-GBM the other hand, IL-4 and IL-10 inhibit IFNc produc-nephritis [7] . Tam et al. reported that exogenous recombinant IL-4 partially blocks development of accelerated anti-GBM nephritis in Sprague-Dawley rats possibly by inducing renal expression of the IL-1 decoy receptor [8] . In a murine model of crescentic glomerulonephritis, Kitching et al. found that IL-4 treatment alone is not sufficient for ameliorating disease but that a combination of two Th2-type cytokines, IL-4 and IL-10, suppresses DTH responses and crescent formation [9] . Studies in lupus-prone mice carrying the lpr gene demonstrated that IL-4 deviates immune response towards a Th2 phenotype (reduced titres of complement-fixing autoantibodies) and protects against nephritis [10] .
IL-4, however, does not always protect against glomerular injury. Peng et al. found that MRL/lpr mice deficient in IL-4 have reduced rather than exaggerated lymphadenopathy and end-organ disease [11] . Overexpression of IL-4 in mice results in B cell hyperactivity, autoantibody formation, and glomerulonephritis characterized by proteinuria, glomerular hypertrophy, -induced autoimmune syndrome [13] . 
Introduction
kidney changes [4] . Furthermore, the initial increase in renal size and function in experimental diabetes is Growth factors have attracted attention in several preceded by a rise in renal IGF-I, IGF binding proteins areas of diabetes mellitus including conceivable effects (IGFBPs) and IGF-II/mannose-6-phosphate recepon the pathogenesis of diabetic kidney disease. In a tor (IGF-II/man-6-P receptor) concentration [2] . recent review article the published evidence for a Moreover, specific changes occur in the renal GH connection between changes in various growth factors:
binding protein (GHBP) mRNA, IGF-I receptor growth hormone (GH ), insulin-like growth factors mRNA and IGFBP mRNA expression in long-term (IGFs), transforming growth factor b ( TGF-b), epidiabetes [2] . Finally, renal effects of potent inhibitors dermal growth factor ( EGF ), platelet derived growth of the GH/IGF-I axis (i.e. long-acting somatostatin factor (PDGF ), tumour necrosis factor a ( TNF-a), analogues and GH-receptor antagonists) have given fibroblastic growth factors (FGFs) and the developfurther evidence for a role of GH and IGF-I in diabetic ment of renal changes in diabetes was covered [1] . The kidney disease. present review attempts to cover the most recent evidence for a causal interrelationship between growth factors and the development of diabetic kidney disease Manipulation of the altered GH/IGF axis in with focus on two of the above mentioned growth diabetic kidney disease factor systems. Accordingly, the first part of the review presents evidence for a pathogenic role of the GH/IGF Long-acting somatostatin analogues system in the development of diabetic renal changes
The potential role of somatostatin and its analogues with emphasis on the renoprotective effects of longin the treatment of human diabetes and long-term acting somatostatin analogues and GH-receptor antagdiabetic complications is based on the probable benefit onists. Secondly, evidence is presented for a causal role of suppressing elevated circulating GH levels in order for TGF-b in the pathogenesis in diabetic kidney to minimize their deleterious effects on diabetic metadisease.
bolism and development of the vascular and functional long-term diabetic changes. Native somatostatin has too short a biological half-life to allow its use in clinical
The GH/IGF axis in diabetic kidney disease therapy, however, the development of new long-acting somatostatin analogues (octreotide and lanreotide) During the last decade attention has been drawn have made experimental and clinical trials possible. In towards GH and IGF-I as mediators of the charactershort-term experimental diabetes 7 days treatment with istic features of early diabetic kidney disease, i.e. renal octreotide or lanreotide from diabetes onset is able to hypertrophy and hyperfunction. Pronounced changes fully inhibit the initial renal hypertrophy through an in the renal GH/IGF-I axis have been demonstrated inhibition of kidney IGF-I accumulation [5, 6 ] . If initiboth in short-and long-term experimental diabetes [2] .
ation of octreotide treatment is postponed 3-9 days Accordingly, experimental diabetes in dwarf rats with after diabetes induction, the diabetic renal hypertrophy isolated GH and IGF-I deficiency is associated with a is only partly inhibited, indicating that early intervenlesser renal and glomerular hypertrophy than observed tion with somatostatin analogues is important [7] . in diabetic control animals with intact pituitary [3] . In
In long-term experimental diabetes, 6 months of addition, diabetic dwarf rats with a diabetes duration octreotide treatment from the day of diabetes onset of 6 months, display a smaller rise in urinary albumin was followed by significant reductions of increase in excretion ( UAE ), indicating that GH and IGF-I may kidney weight, kidney IGF-I levels, and UAE when compared to untreated diabetic rats [8] . A recent study (captopril ) either alone or in combination following 3 months of untreated diabetes [9] . No effect was The transforming growth factor b ( TGF-b) axis in observed of octreotide, captopril or the combined diabetic kidney disease treatment on kidney IGF-I levels, however, octreotide treatment alone and in combination was followed by TGF-b is unique among growth factors in its ability a significant reduction in kidney weight compared to to modulate extracellular matrix production and both placebo treated diabetic rats [9] . Further, the combined glomerular mesangial and epithelial cells increase syntreatment of octreotide and captopril was followed by thesis of extracellular matrix proteins (i.e. protoglya significant reduction in UAE compared to placebo cans, fibronectin, type IV collagen and laminin) in treated diabetic rats giving evidence for a beneficial response to TGF-b. Recent studies have suggested the effect of the combined treatment with octreotide and TGF-b system may play a role in the pathogenesis of an ACE-inhibitor on manifest experimental diabetic diabetic nephropathy. High glucose concentrations renal changes [9] .
increase TGF-b1 mRNA levels in both cultured mesIn clinical studies acute infusion (2-3 h) of octreotide angial cells and proximal tubular cells in vitro [15, 16 ] . to patients with insulin-dependent diabetes mellitus Further, the elevated glucose levels in vitro stimulate (IDDM ) induced a reduction in renal plasma flow TGF-b gene expression and bioactivity, cellular hyper-(RPF ) and glomerular filtration rate (GFR), concom-trophy and collagen transcription in proximal tubules itantly with decreased plasma GH and glucagon levels [16 ] . In addition, interesting experiments have been [10] . In long-term studies octreotide administration for published recently on changes in renal TGF-b in early 12 weeks in 11 IDDM patients induced a significant experimental diabetes in vivo. In a study performed in decrease in the elevated GFR; in addition, total kidney STZ-diabetic rats, an increase in glomerular TGF-b volume was reduced. Three of the patients were mRNA was reported as early as 24 h after the onset re-examined 12 weeks after cessation of octreotide of hyperglycaemia with a sustained increase for up to treatment, and their GFR had risen to the level at the 2 weeks [20] . Increased renal levels of TGF-b mRNA start of the study [11] . No clinical studies have yet in the early renal hypertrophy have also been described appeared on the possible long-term effects of somatos-both in non-obese diabetic (NOD) mice and diabetic tatin analogues on UAE in IDDM patients.
BB rats [18] . Finally, a sustained increase in glomerular TGF-b mRNA levels is seen in long-term STZ-diabetic rats with a diabetes duration for up to 6 months GH-receptor antagonists [19, 20] . Two clinical studies have been published By recognizing the potential role that GH and IGFs dealing with changes in the renal expression of the may play in various pathophysiological conditions, TGF-b system [21, 22] . Increased TGF-b immunoincluding diabetic nephropathy, a series of highly staining was initially described in glomeruli obtained specific antagonists of the GH action has been from diabetic subjects [21] . This observation was condeveloped for the potential therapeutic use. Initially, firmed and further extended in a recent study, in which it was shown that alteration of single amino acids in increased glomerular and tubulointerstitial levels of all the third a-helix of bovine (b)GH (residues 109-126) three TGF-b isoforms were reported in diabetic results in a functional GH antagonist. In vitro experi-nephropathy, but also in several other conditions charments show that the group of GH antagonists binds acterized by accumulation of extracellular matrix [22] . to the GH receptor with the same affinity as native Further, a positive correlation between TGF-b, GH, but in vivo a phenotypic dwarf animal character-fibronectin and plasminogen activator inhibitor-1 levels ized by low circulating IGF-I levels and a proportional in glomeruli and tubulointerstitium was reported [22] . body composition develops when the GH antagonist These studies support the hypothesis that glucose is expressed in transgenic mice. Recently, studies have induced rise in renal TGF-b expression and peptide in reported renoprotective effects of GH antagonists in the kidney may be responsible for some of the renal long-term diabetic transgenic mice that express these changes that precede the development of diabetic GH antagonists (bGH-G119R or hGH-G120R) nephropathy. [12] [13] [14] . Compared with transgenic diabetic mice expressing wild-type bGH or bGH, the diabetic mice expressing GH antagonists showed lesser glomerular Manipulation of the altered TGF-b axis in diabetic damage [12, 13] , no increase in total urine protein [12] , kidney disease no glomerular hypertrophy [14] and no increase in glomerular a1 type IV collagen mRNA levels [14] . Neutralizing antibodies Interestingly, the inhibitory effects of GH antagonists in transgenic mice were seen without alteration in Data supporting the hypothesis that the glucose induced rise in renal TGF-b expression and peptide glycemic control as similar levels in blood glucose and Hb Alc were seen in the different diabetic animals may be responsible for some of the renal changes in diabetic nephropathy have been published in recent expressing wild-type bGH, GH antagonists or bGH [12, 13] . Studies including exogenous administration of elegant studies using neutralizing antibodies. In vitro the glucose mediated increase in type IV collagen GH antagonists to diabetic animals models are needed to elucidate the usefulness of the GH antagonists as a synthesis in mesangial cells is dependent on the autocrine action of TGF-b1 as neutralizing antibodies to potential therapeutic agent. Since the initial description of FSGS in 1956, contro-the study of Newman et al. in the 1970s, [2] . However, subsequent observations including our most recent, versies have been the constant companions of this disease. It is beyond the scope of this editorial to cover long-term follow-up have shown a complete remission rate with treatment of 25-40% in both age groups and the entire area of FSGS but we will review the issues related to pathological variants as well as the influence have suggested the apparent differences in outcome between children and adults may have been the lack of age, gender, race, and treatment response on outcome. Most of the clinical data is based on patients of a trial of therapy in the latter [3] [4] [5] . Even in the elderly the response rate is in the same range although with the 'classic' lesion so this needs definition. Histologically this consists of an area of adhesion the lesion is seen less frequently [6 ] . Recently remissions in up to 60% of patient have been reported in between a peripheral capillary loop of the glomerular tuft and Bowman's capsule, with progressive replace-both age groups with more vigorous treatment including the use of prolonged cytotoxic drugs combined ment of this area with matrix material that gradually increases in size [1] . This leads to the characteristic with high dose corticosteroid therapy but the risks are also noted to be higher. [7, 8] pathology seen on light microscopy, a discrete segmental solidification of the glomerular tuft most commonly found close to the vascular pole.
TGF-b isoforms ( TGF-b 1,2,3) and TGF-b receptors
Race and natural history of focal segmental glomerulosclerosis? 1. Long-term outcome-is there a difference
Racial bias in terms of both incidence and outcome is between children and adults?
another area of interest. Korbet et al. [9] has suggested an increased prevalence of the disease in blacks, in his In the clinical realm it was thought initially that report of 340 patients with nephrotic range proteinuria outcome in patients with FSGS was different in chil-and some regional registries of ESRD support this dren compared to adults. This belief was reinforced by contention [10] . Alternative explanations to a racial predisposition to the development of this disease bias, and failure to separate primary from secondary
hypercellularity and the state of the surrounding glomData from the same United States Renal Data Systems indicates that FSGS is over represented as the cause erular tuft (collapsing type).
The 'glomerular tip lesion' originally described by of renal failure among African-Americans compared to Caucasian children, suggesting a more aggressive Howie and Brewer was thought to behave differently from classic FSGS with a higher response rate to disease in that population but this could be explained by the higher incidence. Regional but more detailed steroid treatment [14] . This observation has not been confirmed in a recent review of this area.
[15] Thus at data presented by Inguli et al. supports the contention that the disease is more severe [11] . They demonstrated present it would be difficult to assign a favorable prognosis based solely on the position of the sclerotic that 78% of black and Hispanic children with this lesion progressed to end ESRD compared to only 33% lesion. This conflicting data is partially related to the difficulty in determining the specific location of the of their Caucasian population. Since the groups were comparable in demographics, observation, time and lesion in this focal and segmental disease since serial sectioning of the tissue has frequently demonstrated a treatment, they suggested that other factors such as race might contribute to this poor outcome. However, surprising variation even within a single glomerulus.
This problem might also apply to the cellular type. the data that prognosis is influenced by race is not unanimous since Rydel et al. did not find this factor Endocapillary as well as extracapillary epithelial hypercellularity usually in a focal and segmental distribution to be predictive of ESRD in their study of 81 adults [4] . Certainly Agarwal et al. in their report on a large characterize this variant. Initially it was thought to be associated with a poorer prognosis but it is now group of Asian patients from India, the majority with the classic lesion found their response to treatment apparent that this outcome is not uniform and the most recent data suggests that perhaps this is an early and long term outcome similar to the white population. [12] phase of FSGS. The last variant, the collapsing type of FSGS was described originally over 10 years ago It is possible that the differences in outcome may be linked to the frequency of the specific type of FSGS and is characterized by the 'implosive retraction' of the endocapillary space as opposed to its classic expanlesion that develops in blacks versus whites. A recent abstract by Hogan-Malton et al. found that their black sion by hyaline and matrix material. The distinguishing clinical features described by Detwiler were the persistpatients were more likely to have the collapsing variant and be less responsive to treatment. [13] Thus, the ence of high grade proteinuria the poor response to corticosteroids, the rapid downhill course to ESRD question of a racial effect on FSGS has not been resolved.
and its predominance in the black population [16 ] . It is interesting to note that only five of the 14 patients in their initial series were given treatment and a
Gender and natural history of focal segmental
response was seen in 20%, not so different from the glomerulosclerosis classic rate. Certainly this type of down hill course is not peculiar to the collapsing variant. Brown et al. [17] described this rapid deterioration in renal function An interesting and relatively unexplored factor is the in 11 patients with the more classic FSGS lesion several influence of gender on outcome and its potential interyears ago. Their emphasis was not on the pathology action with age. Most reported series in children show but on the clinical observation, similar to Detwiler a 151 male to female incidence rate, but adult series group, that persistent heavy proteinuria (>10 g/day) tend to show a 251 ratio. [9] Similarly it is difficult to predicts a very poor prognosis. Our review would ascertain from the literature whether progression is confirm this finding but add the proviso that corticosinfluenced by gender alone since the current published teroids should still be tried since a complete remission data is retrospective, treatment protocols vary widely may occur and lead to an excellent long term prognosis. and the observation periods are often short. In our At this point it seems reasonable to assume that the own recent long-term review the incidence was equal pathological lesions seen in idiopathic FSGS are similar in children by gender as was the rate of complete and but not identical reactions to injury from a variety of partial remission and chronic renal failure but the unknown causative agents, superimposed, perhaps, on incidence in the adult population was 2 males to every a genetic susceptibility [18] . female and the outcome was different i.e. the complete/ partial remission rate favoured women 251 and the chronic renal failure group was the opposite i.e. 2
The splitters versus the lumpers
males to every female. [5] In summary if your penchance is for splitting, the
Variants of glomerular morphology
options for explaining the differences seen in FSGS are virtually unlimited and include many more factors than the ones discussed. This is probably related to The recent spate of articles describing the morphologic variants of FSGS needs to be placed into the context the fact that the response to therapy is based not only 8 . Banfi G, Moriggi M, Sabadini E, Fellin G, Amico GD, on the particular initiating agent but also on the Ponticelli C. The impact of prolonged immunosuppression on underlying demographic factors and others yet to be Introduction environmental factors and multiple genes). Next, molecular variants of candidate genes, i.e. genes with Recent years witnessed a growing recognition of the the potential to modulate these cardiovascular phenogenetic principles of cardiovascular disorders. First, types, were uncovered. Some of these genetic variants the origins of hypertension, coronary artery disease, were found to be associated with altered levels of left ventricular hypertrophy, or progressive loss of circulating proteins or enzymatic activities, e.g. angiorenal function were demonstrated to be multifactorial tensin converting enzyme (ACE I/D), angiotensinogen The ACE I/D polymorphism [1] : 49-55, 57-61, 63]. Of these, 20 studies were in favour of such association. However, while 2053 may The insertion/deletion (I/D) polymorphism of the ACE be a clear cut result in a competitive ballgame, this gene represents a most prominent genetic variant subscore does not necessarily resolve a scientific problem. jected to this ongoing debate. At present, it is undisFurthermore, the game might have been unfair since puted that the I/D polymorphism in intron 16 of the negative studies suffer from publication bias (positive human ACE gene is related to 14-50% of the interindifindings have a higher chance of being published ) such vidual variance of serum ACE activity (for references that even more advanced arithmetics by means of meta see recent review [1] ). Furthermore, increased levels analysis may be inconclusive. of ACE activity were found in lymphocytes and cardiac It may be worthwhile, therefore, to return to the tissue of individuals carrying the ACE deletion allele pathophysiology of LVH and the renin-angiotensin [1] . Unfortunately, the consensus on the ACE I/D system. The general perception is that LVH is a congenotype ends at this point. In particular, the associsequence of arterial hypertension, aortic stenosis, or ations of this polymorphism with a variety of cardioobesity in order to normalize cardiac wall stress. vascular disorders were inconsistently observed when Neurohormonal mechanisms, e.g. the renin-angiotenmultiple populations were investigated [1] .
sin system, are thought to modulate this process [10] . It has to be kept in mind, however, that the renin-angiotensin system is normally under strict negative feed-
Left ventricular hypertrophy and ACE
back inhibition. Thus, genetically enhanced expression of singular components of the angiotensin II forming For the nephrologist, left ventricular hypertrophy cascade may or may not be of physiological relevance. (LVH ) is an important prognostic marker since the Given this information, it may be questionable if the condition is frequently encountered in patients with ACE I/D polymorphism by itself has enough biological renal failure or hypertension. In particular, LVH is significance to substantially increase left ventricular accompanied by a markedly enhanced risk of heart mass in otherwise healthy subjects. In fact, the impact failure, myocardial infarction, and death. Thus, it may of this genetic marker may be too small to be detectable be of relevance to study the ACE I/D polymorphism in groups of <100 subjects. Likewise, M-mode echoin the context of LVH and/or renal failure [1, 2] .
cardiograms carried out during the 70s without 2D However, the first question to ask is whether such guidance may be too inaccurate to uncover subtle analysis is meaningful given the experimental data on differences. In this respect it may be of interest that the role of ACE in LVH. In this regard, it is well the largest negative trial on the association between established that ACE gene expression is induced in LVH and the ACE I/D polymorphism revealed positive experimental and clinical pressure overload LVH [1] .
associations between ACE DD genotype and cardioLikewise, cardiac ACE activity and cardiac vascular phenotypes that are easier to determine angiotensin I to angiotensin II conversion rates were namely blood pressure levels or hypertension status, found to be enhanced in hearts with LVH [1] . Further, that are prominent risk factors for LVH [1] . angiotensin II, has been demonstrated to be a powerful
The impact of a slightly activated renin-angiotensin stimulus of cardiac protein synthesis and growth [1] . system may be more pronounced when the heart is Moreover, ACE inhibition has been shown to ameliorunder stress or the renin-angiotensin system is also ate cardiac hypertrophy independently from effects on activated for other reasons. Thus, chronic arterial or cardiac afterload [1] . Finally, isolated cardiac ACE pulmonary hypertension, aortic stenosis, hypertrophic inhibition (via intracoronary infusion of an ACE inhibor dilatative cardiomyopathy, myocardial infarction, itor) improved diastolic function in patients with renal transplantation, or polycystic kidney disease may chronic LVH. Thus, given the experience with ACE in help to precipitate the consequences of the ACE polyclinical and experimental pressure overload hypermorphism. In fact, the majority of positive association trophy, it seemed plausible indeed to investigate the studies between the ACE DD genotype and elevated role of the ACE I/D polymorphism as a genetic cardiac mass are based on patients with these condimodulator of left ventricular mass. Even more striking tions [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . In other words, the ACE DD genotype support of this idea comes from molecular genetic appears to play a permissive role in the development studies in inbred animals. In particular, the chromoof LVH when the cardiac growth machinery is activsomal locus of the ACE gene was found to be linked ated. An impressive example for this hypothesis is to left ventricular mass (independently of blood presbrought about by most recent data from Montgomery sure) in a cross between Brown Norway and New Zealand hypertensive rats. et al. [11] . The authors studied in a blinded fashion young healthy subjects before and after a rigorous under physiological conditions [12] . However, cardiac growth and diastolic dysfunction were augmented in exercise protocol. Only those participants who carried the same ACE transgenic rats when the animals were the ACE deletion allele displayed an increase of left stressed by abdominal aortic banding and subsequent ventricular mass as estimated by echocardiography, cardiac pressure overload [12] . electrocardiography, or BNP measurements [11] . Thus, Nevertheless, current convincing evidence that demthe ACE genotype may act only under specific condionstrates the role of the ACE I/D polymorphism in tions suggesting an interaction between altered haemothe development of cardiac hypertrophy is lacking and dynamics, ACE, and/or other genetic cofactors in the potential mechanism(s) responsible for the enhanced modulation of left ventricular mass. In agreement with cardiac growth in subjects with the ACE DD genotype this notion are observations of Pinto et al. and Ohmichi remain to be elaborated. In this respect, a molecular et al. who both found pathological remodeling early geneticist cannot escape the principles of pathophysioafter myocardial infarction, predominantly in those logy since molecular genetic association studies may subjects with the ACE DD genotype [1, 5] .
only provide hypotheses rather than proof for bioloThe hypothesis that the system needs to be stressed gical effect. Finally, the clinical usefulness of the ACE to uncover implications of cardiac ACE receives further DD genotype as a molecular marker of LVH appears indirect support from two experimental lines of evidto be rather limited unless we learn how ACE increases ence. First, low concentrations of angiotensin I (the left ventricular mass and whether ACE related cardiac substrate of ACE ) resulted in similar angiotensin I to growth is good or bad for the respective individual. angiotensin II conversion rates in healthy individuals with various ACE genotypes [1] . However, high doses responses in subjects with the ACE DD genotype [1] . Thus, conditions that go along with high renin or angiotensin I levels such as physical exercise, acute References myocardial infarction or heart failure may enhance the Diabetes mellitus causes more end-stage renal disease 77% in the medically-managed group [2] . Data like these suggest that much could be done to prevent or in the western world than any other disease category. Study after study has shown that diabetics have a treat cardiac disease in diabetic ESRD. poorer survival than their non-diabetic ESRD counterparts. About half of this excess mortality can be
Results of the Canadian Study
attributed to cardiovascular causes. It is already known that diabetes is an independent risk factor for coronary artery disease and cardiac failure in non-uraemic popu-We studied a prospective inception cohort of 433 lations [1] .
patients who survived for an average of 41 months, collecting clinical data monthly, and echocardiographic data yearly [3] . At inception of dialysis diabetic
Prevalence of cardiac disease in the diabetic on patients (n=116) had more echocardiographic condialysis centric LV hypertrophy (50% vs 38%, P=0.04), ischaemic heart disease (32% vs 18%, P=0.003) and cardiac failure (48% vs 24%, P<0.00001) than nonFew clinical studies have focused on diabetic dialysis diabetics. Among diabetics, older age was associated patients; most studies combine diabetics and nonwith baseline concentric LVH, systolic dysfunction, diabetic patients together, or exclude diabetic patients. and cardiac failure; anaemia was associated with LV Surprisingly little is known about the natural history dilatation; smoking was associated with symptomatic and risk factors of cardiac disease in diabetic ESRD.
ischaemic heart disease. There was a very striking There is a dearth of basic information, such as the association between left ventricular morphology and prevalence of left ventricular disorders and symptothe presence of cardiac failure at inception of dialysis. matic cardiac disease at the start of dialysis therapy, Compared to those with normal LV dimensions and when in pre-dialysis life they begin, the rate of progrescontractility, the odds of cardiac failure were 5.4 (P= sion of these disorders, the incidence of symptomatic 0.02) in those with concentric LV hypertrophy, 13.7 cardiac disease of new onset, the lethality of cardiac (P=0.02) in those with LV dilatation but preserved events occurring while on dialysis therapy and the systolic function, and 26.7 (P=0.006) for those with nature of cardiac risk factors, specific to diabetics with systolic dysfunction. After starting dialysis diabetic end-stage renal disease. There is a strong temptation patients had similar rates of progression of echocardioto assume that the cardiac problems of diabetic ESRD graphic disorders and new cardiac failure as nonpatients relate to factors in their predialysis life about diabetics, but higher rates of new ischaemic heart which little can be done when they reach dialysis. This disease ( RR 3.2, P=0.0002), overall mortality (RR assumption is probably not justified. For example, 2.6, P<0.0001) and cardiovascular mortality (RR 2.6, Manske et al. randomly assigned insulin-dependent P<0.0001). Mortality was higher following admission diabetic patients with ESRD and significant coronary for clinically-diagnosed ischaemic heart disease (RR artery stenosis (with normal ejection fraction, without 1.7, P=0.05) and cardiac failure (2.2, P=0.0003), typical anginal pain) to medical or surgical managesuggesting that these events are more lethal in diabetics. ment. In 8.4 months of follow-up 15% of the surgical Among diabetic patients older age, LV hypertrophy, group had a cardiovascular end-point, compared with smoking, clinically-diagnosed ischaemic heart disease, cardiac failure, and hypoalbuminaemia were independCorrespondence and offprint requests to: Dr R. N. Foley, Memorial ently associated with mortality. This study confirms University of Newfoundland, The Health Sciences Centre, St John's, Newfoundland, Canada A1B 3V6. the widely held impression that the burden of clinically Smoking cessation, optimal glycaemic control, aggressbe fully attributed to cardiac disease present at incepive blood pressure control, ACE inhibition, aggressive tion; the 'extra' mortality seems to be mediated via treatment of dyslipidaemia and very careful monitoring ischaemic disease, rather than quicker progression of for malnutrition, and avoidance of severe anaemia are cardiomyopathy while on dialysis therapy. Indirectly the cornerstones of preventive management in the prethese data suggests that diabetes accelerates further dialysis phase. There is very little evidence to suggest the 'accelerated atherosclerosis' of uraemia. Of equal that the management of symptomatic cardiac disease importance, this study suggests that are many treatable of diabetics should be different to non-diabetics. The risk factors such as anaemia, smoking, LV hyperbalance of evidence suggests that coronary arteriotrophy, and hypoalbuminaemia.
graphy is indicated for most diabetic transplant candidates. We feel that serial echocardiography is useful and influences clinical management; however, our view-
The cause of cardiac problems in the diabetic
point is likely to be skewed, and it is highly unlikely that a trial comparing a policy of serial echocardiograThere is considerable evidence for a specific diabetic phy versus no echocardiography will ever be percardiomyopathy, characterized by ventricular thickenformed. When diabetic patients reach ESRD we feel, ing beyond that expected for blood pressure levels. For in the absence of controlled data to suggest the opposexample, the Framingham Study found that female ite, that preventive and symptomatic management diabetic patients had larger LV wall thickness, endshould not differ substantially from the pre-ESRD diastolic diameter and relative wall thickness than nonphase. The need for high quality, prospective epidemidiabetic patients, [4] . In our study, diabetic patients ological studies and randomized intervention trials of had a higher baseline prevalence of concentric LV cardiac disease in ESRD is acute; this is more true in hypertrophy than non-diabetic patients; this was diabetic ESRD than other major cause disease especially true in female diabetics. It is not known category. whether this 'diabetic cardiomyopathy' is preventable by good glycaemic control, although this would seem to be an attractive hypothesis. The limited data linking References If the choice of dialysis method were based solely on this method categorically, although many of the technical problems have been overcome and thus there are accepted, strictly medical, criteria a similar percentage of patients should receive the respective type of treat-now far fewer failures. Nevertheless, although the incidence of peritoneal infection is now low, peritonitis ment in economically similar countries. And yet 20 years after the introduction of ambulatory peritoneal due to intra-abdominal pathology is a major complication, particularly in the elderly: this problem may carry dialysis (PD) for treating ESRD patients, the extent of its use differs greatly between countries. Thirty-eight weight when physicians make their choice, a choice which is rarely explained. per cent of patients in Canada, and only 6% in Japan, are treated by PD [1] . Despite well-known imperfecIn theory, the choice between two dialysis techniques tions in data collection, mainly because they depend is only an issue if they result in the same survival and on voluntary reporting to national and European quality of life. There has been no truly prospective, registries, it appears that there are even differences randomized trial, involving a large population of between western European countries: in 1995, 45% of patients of similar age, sex, associated pathology and dialysis patients in Britain and only 7.9% in Germany medical treatment before dialysis, but treated using were treated by PD [1] . These percentages have different methods of dialysis under equivalent condiremained constant for years ( Figure 1 ) and reflect true tions (which are very difficult to verify). No such a differences in the selection of treatment modalities [2] . study has been performed, and is unlikely ever to be There are also regional differences in some countries. performed, for many, mostly ethical reasons. The In northern Italy, approximately 15% of patients are comparison of PD and HD has thus been based on treated by PD, and only 2% in Sicily [3] . In France, retrospective single or multi-centre analyses, or on data similarly, there are large differences in the use of PD, from registries. These studies suffer from sampling bias and the percentage of patients treated by PD can vary and their conclusions are sometimes divergent. from 0% to 22% between different towns in the same However, it is clear that after 3-5 years, very few region [4] . In contrast, PD is used to the same extent patients are still treated by PD, the limits of this throughout the whole of Germany and in Switzerland, method being reached when the dose of dialysis it can with the exception of the canton of Valais provide is no longer sufficient [6 ] . Thus, in the 1990s, (Switzerland), where PD is seldom used [5] .
PD must be viewed not as a potential replacement for There are psychological and social reasons, as well HD, but as an alternative to HD during the early years as medical ones, to explain these disparities. The way of treatment [7] . that care-givers and society view the so-called autoThere is still much debate over the indications, which nomous dialysis methods is important and depends in are based on medical background and underlying renal part on guidelines, which are themselves largely deter-disease, for particular dialysis methods. PD has major mined by economic factors. Here, we analyse the role advantages for very young children and HIV-infected of these different factors in influencing the choice of patients. However, there are very few patients in these treatment modality.
categories throughout western Europe. This cannot therefore explain the observed differences of the percentage of patients on PD between regions and coun-
Medical factors
tries. PD is regarded by some as being ideal for elderly patients, because it provides haemodynamic stability At the end of the 1970s, PD was seen as an alternative and permits treatment of the patient in his/her own to chronic haemodialysis (HD), which had a proven home [8] . Others disagree and prefer HD. It is only in efficacy. The many initial complications led numerous the over 65 age-group that the number of new dialysis medical teams to view PD as an inferior method patients per million population continues to increase ('second class treatment by third class physicians') and annually, to a similar extent throughout the European therefore abandoned its use. Some doctors still reject Union. Thus, this factor is not responsible for the differences shown in Figure 1 , even in Britain, where the number of elderly patients treated is consistently high incidence of diabetes in Scandinavian countries may be responsible for the high prevalence of PD. It treat. It is difficult to recruit devoted physicians and nurses to take care of PD patients, because both has been claimed that PD is the best method for treating diabetic patients, although there is now some technical skill and competence in interpersonal relations are required. The use of PD may also complicate debate about whether this is actually the case [9] . In fact, it is clear that most choices of therapy are based the functioning of HD units, whose back-up is vital to the success of any PD programme. Indeed, PD prolargely on non-medical criteria.
grammes cannot function independently. The difficulties encountered in running such treatment facilities
Psycho-social factors
may partly explain the treatment choices made by some nephrology department directors. Do the patients themselves have differing views In this context, one important factor is the experience about the various treatment methods? In 20-30% of of the doctors involved. In countries with adequate cases, ESRD patients are referred to the nephrologist HD facilities, doctors and medical staff are often late. They are therefore mostly treated by HD, and unfamiliar with PD, and many have never used it. This are unlikely to be taken off HD subsequently [10] . In is particularly true of older physicians in academic non-urgent situations, when they have the possibility institutions. Efforts have been made by the teams that to choose, the decisions of the patients depend mostly pioneered PD, often supported by industry, to educate on the information provided by their doctors. Indeed, other physicians about its use. Despite this effort, its the patient's confidence in the nephrologist has a larger use is still relatively modest. In Europe there is no effect on his decisions than most other considerations. relationship between the number of nephrologists per Various medical teams have very definite, but divermillion population and the proportion of patients gent, opinions on treatment choices. Ignorance, or treated by PD ( Figure 1 ). For example, although there refusal to acknowledge the benefits of patient autoare many nephrologists in Italy, PD is used very little.
nomy leads some doctors to rule out this therapeutic Switzerland and Germany have similar numbers of approach systematically. Therefore, nephrologists are nephrologists per million population (about 30), but, largely responsible for some of the observed differences in Switzerland, 2.5 times more patients are treated by in prevalence of use. This fact is well illustrated in PD than in Germany (17.9% vs 7.9%). Nevertheless, Paris where there are 11 university hospitals: 90% of conclusions in this area should only be drawn with patients treated by home HD come from one of these caution, because the exact numbers and qualifications hospitals and 72% of patients treated by PD come of doctors and nurses who manage ESRD patients are from three others. not known. Doctors may also be concerned that PD The patient's psychological profile, family environincreases the workload of the care team. They will be ment, type of housing, distance from the HD unit obliged to be on call 24 h a day to deal with complications, particularly infections, which can be complex to (particularly important in rural areas) and desire to continue working, all affect the patient's decision to 45% of the available health care and less than 10% of patients are treated by PD. take a more or less active role in treatment. Nevertheless, in Europe, the desire to continue working In some countries, where health care is largely provided by the private facilities (Germany, Italy, is becoming less important in the decision-making process, because the average age of patients at the France), there is no or unfavourable reimbursement by health financing organizations for PD. The availabstart of treatment is close to the age at which retirement is proposed to them to reduce unemployment. ility of grants for patient training also differs greatly and is dealt with separately only in Germany, Spain In some countries, patients receive an indemnity for agreeing to home treatment. The amount given is the and Switzerland. In France, there is no training reimbursement for PD, whereas there is one for home HD. same for all methods and is too small to influence the initial choice. However, in France, legislation makes it The same applies in both France and Switzerland for medical fees and this situation makes it extremely possible to pay nurses who treat patients by PD at home and this clearly influences the choices made by difficult, if not impossible, for private nephrologists to prescribe PD [2, 3] . both doctors and elderly and handicapped patients.
Different mental attitudes also account for some The proportion of the treatment cost accounted for by consumables is much larger for PD (about 70%) choices. Many patients, particularly in southern Europe, choose to be passive when faced with illness. than for HD (about 52%). Also, in countries where reimbursements are paid at a flat rate which depends They feel that they have already paid high contributions for health insurance and they refuse to become only on type of treatment, it is easier for the nephrologist to recover his fixed costs, particularly his staff directly involved in their own treatment. Doctors and medical teams must fight against the patient's unwill-costs, and to increase his own profits, simply by increasing the number of patients treated by HD. In ingness to take responsibility, but teaching unwilling patients how to treat themselves is extremely difficult. contrast, an increase in the number of patients treated by PD causes additional expenditure with proportionAttitudes are probably very different in Scandinavian countries. Strong family support and national solidar-ately less profit for infrastructure and staff. Doctors are probably aware of these considerations, whatever ity may well be at least partly responsible for the success of PD programmes in these countries. These their professional situation, and this inhibits the development of PD programmes. same factors contribute to the success of transplantation programmes, including those involving living
In an economic environment which has become increasingly difficult for health care, the considerable donors.
differences in the choice and cost of dialysis treatments in Europe cause problems and may become an issue which attracts government interest. Nephrologists
Economic factors
cannot be indifferent to this scenario. Together with health financing organizations, they must try to improve the cost-effectiveness of techniques before The cost of PD is about 30% less than that of centre HD, regardless of country, health care system or seeking additional funds. It is their role as doctors to assure the best possible quality of treatment for their funding body. This difference tends to lessen as larger quantities of dialysate and often, a cycler, are required patients and it is their role as citizens to ensure the best possible use of available funds. They should for adequate PD. In Great Britain, a policy of strictly limiting the funds available for HD was and continues therefore look with open minds at all new technologies, both in the phase of their evaluation and subsequent to be the reason for the great success of PD programmes. In France, the number of HD centres is use. Inflexible attitudes can only damage attempts to provide the best treatment at the lowest cost. This is limited for legal reasons, and free access to PD thus allows a large number of elderly patients to receive the only way to ensure that certain categories of patient, particularly the elderly, do not in the coming dialysis treatment. Indeed in 1992 in France, 28% of patients aged 75 and over were treated by PD compared months and years, become victims of unequal access to dialysis treatment. to less than 10% in the total dialysis population [8] . The proportions were the other way around in the US. Such contrasts cannot be considered satisfactory and presumably reflect inappropriate choice of PD for References some patients who should have access to HD. in CAPD patients: a retrospective study of a 10-year period. Nephrol Dial Transplant 1995; 10: 1905-19011 In contrast, in Spain, the public sector provides only
Introduction
shown that semiallogenic [6 ] and fully allogenic experimental bone marrow transplantation (BMT ) between Aside its basic biological function of self/non-self discongenic strains of mice [4] change the odour type of crimination in the immune system the major histocomthe recipient in the way that old (recipient) and new patibility complex (MHC ) has been recognized as a (donor) odour components characterize the chimeras. possible source of individual specific body odours.
In other words: with the BMT a donor-specific H-2 Dating back to speculations by Lewis Thomas in 1975 odour component was added to the recipient's odour [1] on the role of the extraordinary polymorphism of profile. Therefore it was concluded that the haematothe MHC as background of an individual chemosenpoetic stem cell is one source of the MHC-associated sory identity, and to early observations of MHC odour signature. dependent mate choice in inbred strains of mice systemThe biological significance of H-2 related odours atic experimental studies by Yamazaki et al. [2] was documented in three quite different paradigms. revealed a first evidence for H-2 related body odours in this species. Meanwhile a large number of animal First of all the above mentioned unsystematic observastudies with rodents and a series of field studies and tions of H-2 dependent mate choices were tested under experiments with humans have extended our know-experimental conditions [7] . As it turned out the prior ledge of MHC related odour signals and substantiated results could be replicated and moreover it was the hypothesis of immunogenetic associated reported that the phenomenon is dependent on the odourtypes. Its potential role in kin recognition, mate odour imprinting from the parents which raised the selection, and social perception is currently under pups. In this case mating preferences serve to avoid debate.
mating with mice that share the same MHC as the foster parents [8] . Secondly it was found that H-2 related odours are capable of inducing the so-called
MHC specific odours in rodents
pregnancy block phenomenon. In the animal literature, pregnancy block is defined as odour-induced return to The most convincing series of experiments were con-oestrous after insemination caused by confrontation ducted with mice which were trained in olfactory with the scent of a male genetically different to the discrimination between two congenic inbred mouse-stud. The odour of H-2 different compared to H-2 strains, e.g. BALB/k (H-2k) vs BALB/c (H-2d ) [3] [4] [5] . similar potential new mates leads in a higher proporThe trainings were performed in an odourized Y-maze tion of newly inseminated mice to this pregnancy block. in which the previously water deprived animals had to Finally a field study by Potts et al. [9] which was identify which of the two in the goal regions of the conducted under seminatural conditions reported the maze randomly presented odours was associated with increase of H-2 heterozygous F-generations in populaa reinforcement: correct choice of one end of the maze tions of mice with well defined H-2 types on a geneticwas reinforced by a drop of water. Several reports of ally diversified background. successful odour discrimination of congenic strains in For rats Roser et al. [10] reported RT.1 related different laboratories led to the conclusion that the odour differences when they tested repeated olfactory H-2 complex is involved in the constitution of odour explorations of urine odour samples from RT.1 contypes. Moreover using the same experimental approach genic strains. In these habituation-dishabituation tests rats first reduced their olfactory exploration (defined number of recurrent identical odour probes. Intro-ducing an odour signal that differs from the scent to Moreover the results from Eggert et al. [17] point to the conclusion that the MHC and other autosomal which the animal is adapted immediately increases the exploration time (dishabituation). By means of this genes interact in producing the specific odour of an inbred strain. Recently Singer et al.
[18] again compartechnique RT.1 related odour types were documented. Furthermore the authors suggested that soluble deriv-ing congenic strains of mice (H-2k vs H-2b) reported that the MHC-determined urinary odour is composed ates of MHC class I molecules in the serum of the animals could selectively bind characteristic odour of a mixture of eight volatile carboxylic acids, the relative concentration of which characterizes the molecules which are excreted in the urine [11] . specific odour profile. In this study no specific components were found. Thus, it remains controversial whether MHC specific odours in humans the MHC odour specificity is also signalled by a small number of specific chemical components besides First evidence for HLA related urine odours was dependence on a profile of different concentrations of reported by our group [12] . We used a computer ubiquituous odour compounds. This may even differ controlled olfactometer in which rats were trained to from inbred strain to inbred strain. discriminate successively presented odours in a so called go-no go discrimination learning paradigm.
Models of MHC related odour production
Urine odour probes were collected from two groups of six subjects each. One group was defined by its common HLA-class I A1,-, B8,-notation (half of the There are at least three different hypotheses about the subjects being homozygous, the other half heterozyg-mode by which MHC specific odours are generated: ous). The second group consisted of members without (i) selective binding of odour molecules to soluble an A1,-, B8,-tissue type and differed among all of its derivates of MHC class I receptors [11] , (ii) MHC members according to their HLA-class I pattern. After specific selective bacterial colonizing. Data from two a cumulative discrimination training procedure the studies with germ-free mice and rats are contradictory animals were able to identify the specific A1,-, B8,- [19, 20] , (iii) Coexpression of odour producing genes HLA related odour and to discriminate it from that lying in the MHC region. Results from studies with of HLA-different persons. Meanwhile field studies mutant mice differing only in single genes of the MHC [13, 14] and an experiment [15] revealed that the simil- [21] as well as studies with HLA-transgenic mice arity in the HLA class I genotype of two persons [22] present evidence that indeed the MHC genes influences social perception measured by ratings of themselves are involved in the odour production. familiarity, attractiveness or pleasantness. Similarity of Summarizing results of our own research and that of the class I HLA in these studies was defined by the other authors we would propose the following integratnumber of shared HLA class I alleles.
ive model (cf. Figure 1 ) in which soluble MHC proteins play a central role in the production of MHC-associated odours.
Chemical characteristics of MHC related odour signals
While behavioural experiments, studies on odourtransfer by experimental BMT, studies of mating preferences and of odour-induced pregnancy block strongly suggest the existence of MHC associated odour types, there is only scattered evidence for the chemical characterization of the volatile signals. Schwende et al. [16 ] used gas chromatography to describe a correlation between H-2 relatedness and the similarity of the chromatograms of volatile components of the respective urine odours of mice. Comparing chromatographic odour profiles of the congenic strains BALB/k (H-2k) and BALB/c (H-2d ) with that of C3H (H-2k) (BALB/k and C3H being different with respect to their genetic background but identical in their H-2) Eggert et al. [17] concluded that a small number of specific chemical mental bone marrow transplantations in mice the haematopoietic components (two out of 55 in their study) as well as a system as well as other tissues and organs were identified as being pattern of a few ubiquituous components differing in the origins of MHC-associated odours. Immunological studies showed that soluble MHC proteins originating from these tissues their relative concentrations between inbred strains can be found in serum. The intact molecules and degraded moieties characterize the H-2 signature of the urine odours.
of these MHC proteins occur in urine as well as in sweat. By an They also identified eight (out of 55) components that unknown process these specific peptides seem to be linked to specific are associated with the genetic background, i.e. profiles of volatile substances, which are detectable and can be described by means of gaschromatographic analyses. describe odour differences between C3H and BALB/k.
